

November 14-16, 2018 | Boston, MA

www.microbiome-gba.com



MICROBIOME MOVEMENT GUT-BRAIN AXIS

Demonstrate Disease Causality of the Gut-Brain Axis & Bridge the Translational Gap Between the Human Gut Microbiome & Effective Treatments

Expert speakers include:



David Donabedian
CEO
Axial Biotherapeutics



Gil Sharon
Postdoctoral Scholar,
Mazmanian Lab
California Institute of
Technology



Felice Jacka
Director, Food & Mood Centre
Deakin University



Phil Strandwitz
Co-Founder &
CEO
Holobiome



Kuldip Dave
Director, Research
Programs
Michael J. Fox Foundation



Valerie Taylor MD
Psychiatrist-in-Chief
Women's College Hospital



Natalia Palacios
Assistant Professor
UMass Lowell



Kathleen Shannon MD
Detling Professor & Chair
University of Wisconsin
School of Medicine and
Public Health



Jane Foster
Associate Professor
McMaster University

Proud to Partner with:



Tel: +1 617 455 4188

Email: info@hansonwade.com

@MicrobiomeDaily



Welcome to the 2nd Microbiome Movement - Gut-Brain Axis 2018

 The ongoing explosion of publications and translational activity within the human microbiome have revealed new insights into the microbiome gut-brain axis, the bidirectional communication 'highway' linking the CNS with gut microbiota diversity and composition. Emerging pre-clinical and clinical evidence suggests the gut-brain axis may provide new clues in the early onset, pathogenesis and treatment across a range of brain-related disorders with current un-met needs.

Part of the industry defining established Microbiome Movement, the 2nd Microbiome Movement - Gut-Brain Axis 2018 returns this November to help large pharma, biotech and forward thinking research institutes deepen their understanding with the fundamental mechanisms

of action and develop targeted treatments across a range of complex disease indications.

Through data driven case studies showcasing the latest pre-clinical and clinical research, uncover the role of multiple metabolic and immune-mediated pathways that are being proven to show an effect in the cause and development of CNS disease. This is your chance to tap into a unique network of like-minded researchers and capitalize on this exciting therapeutic opportunity. 



Alexander Puttick

Program Director & Co-Founder
The Microbiome Movement

The Numbers That Matter



18+

Case
Studies



8+

Hours
Networking



1

Dedicated
Pre-Conference
Workshop



1

Scientific
Poster
Session

Five Reasons to Attend the Microbiome Movement – Gut-Brain Axis Summit

1.

Discover the impact of the microbiome gut-brain axis across critical CNS conditions including Parkinson's, ASD, Bipolar Disorder, Stress & Depression



2.

Assess the translatability of *In-vivo* models when making sense of microbiota-host mechanisms



3.

Learn to design and develop effective clinical studies that evaluate the impact of the microbiome gut-brain axis in human populations



4.

Learn the successes from industry when translating promising results into effective therapeutic candidates



5.

Understand the role of Diet and Nutrition on mental health based on promising evidence gained from the microbiome gut-brain axis



JOIN THE MICROBIOME MOVEMENT



January 2019: Paris, FR
microbiome-europe.com

 The event organization and content was flawless. This is a premier event for the microbiome biotech and pharma industry 
Jim Brown, Senior Fellow Director in Computational Biology, GSK



February 2019: Raleigh, NC
microbiome-agbiotech.com

 Possibly the best conference in the agricultural microbiome space - a great mix of basic scientific research and product development from universities, multinationals and start-up companies. Congratulations! 
Marcus Meadows-Smith, CEO, BioConsortia



May 2018: St. Louis, MO
microbiome-animal.com

 This was a great opportunity to meet the critical innovators within Animal Health and learn more about how technologies from the microbiome are addressing key problems in this space 
Megan Lyman, Director, IP, Regulatory & Product Development, AgTech Accelerator



June 2018: Boston, MA
microbiome-summit.com

 This meeting is possibly the best in the microbiome field for a biotech company, for networking and hearing the latest developments 
Mike Romanos, CEO, Microbiotica



November 2018: Boston, MA
microbiome-nutrition.com

 If you want to learn about the latest developments and mix with the movers and shakers in the industry, you HAVE to be there 
Alan Murray, CEO, NextFoods



November 2018: Boston, MA
microbiome-gba.com

 It is one of the best meeting I've been to! Great job! 
Yanjiao Zhou, Research Scientist, The Jackson Laboratory

MEET THE EXPERTS



Patrice Garnier
CEO
Amabiotics



David Donabedian
CEO
Axial Biotherapeutics



Chris Reyes
Co-Founder & CSO
Bloom Science



Gil Sharon
Postdoctoral Scholar,
Mazmanian Lab
California Institute of Technology



Felice Jacka
Director, Food &
Mood Centre
Deakin University



Elaine Patterson
Senior Scientist
DuPont Nutrition & Health



Malu Tansey
Professor
Emory University School of Medicine



Ulrich Thienel
Chief Medical Officer
Finch Therapeutics Group



Phil Strandwitz
Co-Founder & CEO
Holobiome



Derrick Macfabe MD
Co-Founder & Director
Kilee Patchell-Evans Research Group



Jane Foster
Associate Professor
McMaster University



Kuldip Dave
Director, Research Programs
Michael J. Fox Foundation



Sian Hemmings
Associate Professor,
Department of Psychiatry
Stellenbosch University



Christian Furlan Freguia
Director of Research
Synthetic Biologics



Nader Yaghoubi
President & CEO
Symbiotix Biotherapies



Valerie Taylor MD
Psychiatrist-in-Chief
Women's College Hospital



Natalia Palacios
Assistant Professor
UMass Lowell



John Lukens
Assistant Professor
University of Virginia School of Medicine



Kathleen Shannon MD
Detling Professor &
Chair
University of Wisconsin School of Medicine and Public Health

WORKSHOP DAY

WEDNESDAY, NOVEMBER 14

Pre-Conference Workshop

Food for Brain Health: Understanding the Potential of Nutritional Psychiatry Through the Gut-Brain Axis

13:00 – 16:00

With depressive disorders the leading source of disability globally, the identification of new target for prevention and management is imperative.

Extensive pre-clinical and clinical data have begun to show that diet-induced gut microbiota modulations play a key role in the regulation of mental health and brain function. Amongst the many external factors that influence overall gut microbiota composition, dietary interventions may be utilized as a clinical strategy for improving mental and overall brain health.

In addition, the use of widespread clinical experiments within the food and nutrition community may point the scientific community to understanding the mechanistic role of the gut microbiome within a number of key CNS based disorders.

Join a internationally-recognized leader at the heart of Nutritional Psychiatry to better understand:

- The importance of Nutritional Psychiatry across a number of mental disorders including depression, anxiety and schizophrenia
- The role of diet in parents prior to conception and in pregnant mothers and their children
- How recent clinical studies are showing how diet-induced gut microbiota modulations are affecting brain health and behavior
- The enormous potential of developing nutritional interventions to help prevent and treat mental, neurodevelopmental and neurodegenerative disorders



Workshop Leader

Felice Jacka

Director, Food & Mood Centre

Deakin University

Professor Felice Jacka is an NHMRC Career Development Fellow at Deakin University where she is director of the new Food & Mood Centre. She is founder and president of the International Society for Nutritional Psychiatry Research (ISNPR) and immediate past president of the Australian Alliance for the Prevention of Mental Disorders (APMD). Professor Jacka has pioneered and led a highly innovative program of research that examines how individuals' diets interact with the risk for mental health problems. Her current work focuses closely on the links between diet, gut health and mental and brain health. This research is being carried out with the ultimate goal of developing new, evidence-based prevention and treatment strategies for mental disorders.

 Everyone who is important in this field, we're seeing them here. This is a great forum to keep up with the progress and stimulate innovation within our own programs 

Ken Blount, Chief Scientific Officer, Rebiotix

CONFERENCE DAY ONE THURSDAY, NOVEMBER 15

7.50 Registration & Morning Coffee

8.50 Chair's Opening Remarks

The Role of the Gut-Brain Axis in Neurodegenerative Diseases



Kuldip Dave
Director, Research
Programs
**Michael J. Fox
Foundation**

9.00 MJFF Activities in Understanding the Parkinson's Disease Microbiome



Natalia Palacios
Assistant Professor
UMass Lowell

9.30 An Epidemiological Study of the Gut Microbiome in Parkinson's Disease



Malu Tansey
Professor
**Emory University
School of Medicine**

10.00 The Role of rgs10 in the Gut-Brain Inflammatory Axis in Parkinson's Disease



10.30 Morning Refreshments & Speed Networking

Building Robust Preclinical Packages – From Mouse to Mechanism



Jane Foster
Associate Professor
**McMaster
University**

12.00 Translational Approaches to Help Make Sense of Microbiota-Host Mechanisms

- Reverse translation approaches in mice provide insight into how gene-environment interactions influence the microbiome
- Host-microbe communication is reciprocal and influences brain structure, gene expression of stress-related and plasticity-related genes, stress-reactivity, and behavior
- Big data and data sharing in a rapidly advancing field

The Role of the Gut-Brain Axis in Neurodevelopmental Conditions



Derrick Macfabe MD
Co-Founder & Director
Kilee Patchell-Evans Research Group

12.30 Short Chain Fatty Acids- Microbial Modulators of Metabolism, Mitochondria and Mind- Implications in Neurodevelopmental Disorders

- Discussing mechanisms derived from translational models and human populations where small molecule metabolites of the host microbiome may effect brain function and behavior
- How are levels of these small molecules altered in relation to diet, birth practices, microbial populations, antimicrobials, metabolic intermediates and genetic endophenotypes
- Are there potential therapeutic mechanisms to modulate small molecule metabolite metabolism to treat or prevent neuropsychiatric disease, or develop screening mechanisms for those “at risk” for these conditions



13.00 Lunch and Networking



Chris Reyes
Co-Founder & CSO
Bloom Science

14.00 Connecting the Gut Microbiota to Diet, Metabolism, Neural Activity and Behaviour to Develop Effective Microbiota-Based Treatments for Epilepsy and Improved Brain Health



John Lukens
Assistant Professor
University of Virginia School of Medicine

14.30 Critical Roles for Microbiota-Mediated Regulation of the Immune System in a Prenatal Immune Activation Model of Autism

- Autism has been recently associated with dysregulated immune responses and altered microbiota composition
- Outlining a new study reporting the critical role for prenatal microbiota in the development of behavioural abnormalities in a murine model of autism
- Discussing results that show the microbiota landscape can influence neurodevelopmental disease pathogenesis



Gil Sharon
Postdoctoral Scholar,
Mazmanian Lab
California Institute of Technology

15.00 Microbiomes of Autism Spectrum Disorder Patients Induce Behavioral Deficits in Mice

- ASD fecal Microbiomes elicit behavioral deficits in colonized C57Bl/6J mice.
- Colonization by ASD microbiomes changes the fecal and serum metabolome
- Specific metabolites increased in control samples can prevent behavioral deficits in the BTBR mouse model of ASD



15.30 Afternoon Refreshments and Networking

Clinical Trial Design & Development for the Microbiome Gut-Brain Axis



Valerie Taylor MD
Psychiatrist-in-Chief
**Women's College
Hospital**

16.00 Safety and Efficacy of Fecal Microbiota Transplantation in a Population With Bipolar Disorder

- Introducing the growing evidence linking the intestinal microbiota with the CNS in psychiatric illnesses
- Sharing a new clinical study to assess the effectiveness of targeting the GBA through FMT, to treat bipolar depression
- Discussing key considerations within clinical study design and objectives within a breakthrough area



Ulrich Thienel
Chief Medical Officer
**Finch Therapeutics
Group**

16.30 LBP Clinical Trial Considerations for Autism Spectrum Disorder



Kathleen Shannon MD
Detling Professor &
Chair
**University of
Wisconsin School of
Medicine and Public
Health**

17.00 Searching the Intestinal Environment for Clues to the Etiopathogenesis of Parkinson's Disease

- Epidemiological and clinical/pathological studies in Parkinson's disease lend credence to the concept of gastrointestinal dysfunction as a driver of pathology in the disease
- 11 Published studies suggest microbiome changes in early and advanced Parkinson's disease as well as in the Parkinson's prodrome
- Preclinical evidence supports a role of dysbiosis in Parkinson's disease

17.30 Panel Discussion: Conducting Clinical Trials in the Gut-Brain Axis: Challenges and Opportunities



Valerie Taylor MD
Psychiatrist-in-Chief
**Women's College
Hospital**



Kathleen Shannon MD
Detling Professor & Chair
**University of Wisconsin
School of Medicine and
Public Health**



Felice Jacka
Professor
Deakin University

18.00 Chair's Closing Remarks

18.10 Close of Conference Day One and Evening Drink's Reception Hosted by the Microbiome Movement



18.10 Scientific Poster Session

After the formal presentations have finished, the learning and networking carries on. The Poster Session is an informal part of the conference agenda, allowing you to connect with your peers in a relaxed atmosphere and continue to forge new and existing relationships.

 The 2017 Microbiome Movement -Gut-Brain Axis Summit was an extremely worthwhile opportunity to connect with academic and industry leaders in this exciting new field 

Mihai Cirstea, Researcher, Finlay Lab, University of British Columbia

CONFERENCE DAY TWO

FRIDAY, NOVEMBER 16

8.20 Registration & Morning Coffee

9.20 Chair's Opening Remarks

The Role of the Gut-Brain Axis in Neuropsychiatric Conditions



Elaine Patterson
Senior Scientist
DuPont Nutrition & Health

9.30 DuPont HOWARU® Probiotics Show Positive Impact on Stress and Anxiety Attributes



Christian Furlan Freguia
Director of Research
Synthetic Biologics

10.00 Treatment of Female Mice with Intestinal Alkaline Phosphatase Ameliorates Behavioural Disorders in Offspring

- New insights into the role of maternal stress in Autism-like disorders
- Role of the GI tract and the microbiota in the development of cognitive disorders
- Treatment of maternal stress with an oral protein ameliorated cognitive behaviours in the offspring

The Role of the Gut-Brain Axis in Stress, Trauma and Injury



Sian Hemmings
Associate Professor,
Department of
Psychiatry
Stellenbosch
University

10.30 The Microbiome in Posttraumatic Stress Disorder and Trauma-Exposed Controls: An Exploratory Study



11.00 Morning Refreshments and Networking

Application of the Gut-Brain Axis into Viable Therapeutics: Commercializing Science in Success



Patrice Garnier
CEO
Amabiotics

11.30 From Microbiome Explorations to Effective Innovative Therapies in Parkinson Disease

- From biochemical mechanisms to proof of concept: how to design a new strategy for Parkinson Disease
- Access patient microbiome information's: a way for personalized treatment
- Preclinical and clinical trials: the same road as pharmaceutical development?

 Phil Strandwitz Co-Founder & CEO Holobiome	12.00 Neurotransmitter and Neurotransmission Modulating Bacteria of the Human Gut Microbiota • How the microbiota appears to influence the central and enteric nervous systems • Key neurotransmitters and neurotransmission systems that are modified by the microbiota • How to consider drugging these systems
 David Donabedian CEO Axial Biotherapeutics	12.30 Targeting the Gut Microbiome to Treat Neurological Conditions: Elucidating a Causal Relationship Between the Gut & Disease • Harnessing the link between the gut microbiome and CNS using a suite of in vitro and in vivo approaches to develop a new class of therapeutics in ASD and Parkinson's • A discussion of AB-1224, a first-in class commensal bacteria-based intervention for the treatment ASD and a summary of promising preclinical data • Reviewing the current hallmarks of success and looking to the future
 Nader Yaghoubi President & CEO Symbiotix Biotherapies	13.00 TREG-Modulating Molecular Therapeutics for the Treatment of Multiple Sclerosis • Recent evidence emerging from human microbiome studies are establishing differences between the microbiota of normal subjects and MS patients • Symbiotix Biotherapies has been developing a novel class of molecular therapeutics based on molecules derived from gut microbiota • These molecules function via a first-in-class mechanism that results in activation of regulatory T cells, and we have been exploring therapeutic application to MS
	13.30 Chair's Closing Remarks
	13.40 Close of 2nd Microbiome Movement – Gut-Brain Axis Summit 2018

 Once again the organisers pulled off a really great conference for keeping up with the microbiome field and networking with colleagues 

Mike Romanos, CEO, Microbiotica

PROUD TO PARTNER WITH



Expertise Partner

Microbiome Insights provides state-of-the art microbiome analysis and bioinformatics. Our end-to-end service starts from experimental design and sample collection to data analysis and bioinformatics interpretation. Microbiome Insights is focused on providing our clients a deeper understanding of functions and interactions of microbial communities across a range of human, animal, agricultural and environmental research applications.

www.microbiomeinsights.com



Expertise Partner

DuPont Nutrition & Health, a business unit of DowDuPont Specialty Products Division, combines in-depth knowledge of food and nutrition with current research and expert science to deliver unmatched value to the food, beverage, pharmaceutical and dietary supplement industries. Our probiotic cultures are scientifically proven to help keep the digestive system running smoothly and to support the body's immune system. They give you the opportunity to add documented health benefits to your products

www.danisco.com/dietary-supplements



Exhibition Partner

Quay Pharma is experienced in formulation development and is one of very few companies licensed to provide clinical manufacturing materials containing live bacterial strains being targeted for delivery to, and in, the digestive, urogenital, otorhinologic and pulmonary tracts. Understanding the client dosing requirements for the live biotherapeutic, Quay can prepare a formulation development strategy to bring your live bacterial strain rapidly and effectively to First in Man studies aiming to provide a formulation with the best chance of clinical outcome.

www.quaypharma.com



Exhibition Partner

Accelerate and transform your research across the entire project lifecycle and capitalize on the diverse opportunities of the microbome. Diversigen provides comprehensive microbiome, metagenomics, host genetic services, customized study design, and complex data analysis - all focused on solutions to improve human and animal health, environmental conditions, and agriculture production worldwide.

www.diversigen.com



Exhibition Partner

Chunlab Inc. is a bioinformatics analysis company specializing in microbiology and Next Generation Sequencing (NGS). Our mission is to simplify bioinformatics and enable clients to easily perform high-end analysis of their NGS data. While other companies deliver massive amounts of NGS data in Excel or text file formats, ChunLab provides in-depth bioinformatics analysis and the results delivery via our suite of convenient web-based solution, BioPlug

www.chunlab.com, www.bioiplug.com

BECOME A PARTNER



Adam Haras-Gummer
Commercial Director
The Microbiome Movement

E: adam.haras-gummer@hansonwade.com

T: +1 617 455 4188

Tel: +1 617 455 4188 **Email:** info@hansonwade.com

www.microbiome-gba.com  **[@MicrobiomeDaily](https://twitter.com/MicrobiomeDaily)**





THE PROMISE OF THE MICROBIOME MOVEMENT

Dear Microbiome Enthusiast,

MM As the knowledge of the microbiome continues to deepen, *The Microbiome Movement* has become more committed than ever to work alongside innovative researchers and industry leaders to build events that focus on applied science and translate cutting-edge microbiome R&D into safe, effective and commercially successful products across a number of industry-specific verticals.

Positioned at the heart of pharmaceutical, agricultural, nutritional and animal health R&D, *The Microbiome Movement* continues to help accelerate the discovery, development and delivery of breakthrough solutions to global challenges to benefit human health. For each specific industry where the microbiome will have a real impact, we're building an exclusive community for you to maximize the opportunity.

We build every event from six key pillars to make sure everything you read, watch and experience will truly help you gain better insight and ultimately help drive the microbiome community together.

This is our promise to you. MM



Passion

We love this space and believe in its long term impact, and we know you do too



Integrity

Showcasing only the most cutting-edge and scientifically validated research, data and best practice into our programs



Quality

Deep market research allows us to cut through the noise and share relevant insights that are important to you



Specificity

Each event agenda is independently designed and curated with a clear narrative to suit your industries' needs



Originality

Adapting with a fast growing community to accelerate your research across healthcare, agriculture and beyond



Trail-Blazing

Staying one step ahead of the latest opportunities and trends, to keep you informed and help make better commercial decisions

**We really hope you can join us on this journey and be a part of the microbiome revolution.
Long Live The Microbiome!**



Alexander Puttick
Program Director & Co-Founder
The Microbiome Movement

READY TO REGISTER?

3 EASY WAYS TO BOOK


microbiome-gba.com/register


Tel: +1 617 455 4188


Email: register@hansonwade.com


One of the best agendas and audiences I have experienced in the past two years in this space



Bruce Caldwell, CEO,
3BarBiologics

SECURE YOUR PLACE

Industry	Register by Friday, September 14	Standard Price
Conference + 1 Workshop	\$2299	\$2699
Conference Only	\$1799	\$2199
Workshop Only	\$599	

Start-up and Academic*	Register by Friday, September 14	Standard Price
Conference + 1 Workshop	\$1899	\$2299
Conference Only	\$1299	\$1699
Workshop Only	\$599	

Team Discounts

Maximize value for money using special team discounts:

- **10% discount – 2 delegates**
- **15% discount – 3 delegates**
- **20% discount – 4+ delegates**

Please note that discounts are only valid when two or more delegates from one company book and pay at the same time. Group discounts cannot be used in conjunction with other discount codes or offers, other than the early booking rates.

For more information on group discount eligibility, rates and booking, please contact: register@hansonwade.com

*Start-up and academic rates are subject to organizer approval. Please visit event website for further details, or email: register@hansonwade.com to apply

VENUE

Hilton Boston Woburn

2 Forbes Road, Woburn, MA 01801

Phone +1 781-932-0999

For further information or assistance, please visit

www3.hilton.com/en/hotels/massachusetts/hilton-boston-woburn-BOSBWHF/index.html

Full payment is due on registration. Cancellation and Substitution Policy: Cancellations must be received in writing. If the cancellation is received more than 14 days before the conference attendees will receive a full credit to a future conference. Cancellations received 14 days or less (including the fourteenth day) prior to the conference will be liable for the full fee. A substitution from the same organization can be made at any time.

Changes to Conference & Agenda: Hanson Wade reserves the right to postpone or cancel an event, to change the location or alter the advertised speakers. Hanson Wade is not responsible for any loss or damage or costs incurred as a result of substitution, alteration, postponement or cancellation of an event for any reason and including causes beyond its control including without limitation, acts of God, natural disasters, sabotage, accident, trade or industrial disputes, terrorism or hostilities. Data Protection: The personal information shown and/or provided by

you will be held in a database. It may be used to keep you up to date with developments in your industry. Sometimes your details may be obtained or made available to third parties for marketing purposes. If you do not wish your details to be used for this purpose, please write to: Database Manager, Hanson Wade, Suite A, 6 Honduras Street, London EC1Y 0TH

Tel: +1 617 455 4188 Email: info@hansonwade.com

www.microbiome-gba.com  [@MicrobiomeDaily](https://twitter.com/MicrobiomeDaily)

